Blogs

Medicare
Industry analysis

-- min read

Turquoise Is Now A CMS Qualified Entity

Which means CMS certified us to work with Medicare claims data

August 18, 2026
Turquoise Is Now A CMS Qualified Entity

Turquoise has just been certified as a Qualified Entity (QE) under the Centers for Medicare & Medicaid Services' Qualified Entity Certification Program.

It's not every day the federal government certifies we know how to handle America's most sensitive healthcare data. For those who don’t know, that means CMS reviewed how we ingest, secure, manage, and report on protected health information and claims data, and decided we're trustworthy enough to work with Medicare's data. Earned only by proving your data pipeline unimpeachable and your data practices of the highest order, the QE designation is an honor, and we're even more excited to dig into the new data now available to us as a QE.

Medicare claims data under Parts A, B, and D is heading to Turquoise soon

As a QE, in the coming months, we'll be able to access and report on Medicare claims data under Parts A, B, and D. 

That means we’ll soon have:

  • Actual utilization and payment data
  • Care settings price transparency data doesn’t currently touch (like skilled nursing facilities, home health, hospice, DME, and physician office claims) 
  • Part D prescription drug event data (pharmacy benefit, fill-level detail)
  • Diagnoses and clinical context
  • Longitudinal patient journeys
  • Payment adjudication detail

How is this different from the commercial claims data we already coupled with price transparency data? Well, commercial claims data is licensed from an aggregator, originally submitted by entities that choose to share it. That data is good but not reliably robust (hence why it acts as a great accompaniment to price transparency data!). Since almost every provider in the country submits claims to Medicare, Medicare data doesn’t suffer from the same gaps as commercial claims. Even a sample of Medicare data is universal in a way commercial claims isn't—there's no market segment Medicare misses, because there's no provider it doesn't touch. Alongside the commercial payer focus of MRF payer rates, this data set is focused on a different population (since Medicare data skews older and sometimes sicker than a commercially insured population) and a different level of granularity.

Basically, as a QE, we can now work directly with charge, payment, and utilization data alongside negotiated rate data. In addition to this new data, as a QE, we’re now required to report on CMS-approved provider performance measures. More on that soon!

It’s not just more data, it’s another piece of the complexity puzzle

This new data sharpens the resolution of Clear Rates—the foundational model of the rates, rules, and relationships underlying how U.S. healthcare gets paid and the foundation of the Turquoise platform. That directly strengthens our ability to simplify the financial complexity of healthcare. Once the data is in hand, we’ll be able to continue to evolve the PATIENT Framework’s Standard Service Packages (SSPs), our open-source, patient-first grouping methodology that collapses the revenue cycle to a single encounter-level price, reducing administrative overhead and enabling guaranteed upfront costs for patients. 

Take a knee replacement, for example. Does that SSP look identical for a commercially insured patient and a Medicare patient, or does it diverge in ways the aggregated data can't show? Right now that's a real question we’re unable to answer. With claims-level Medicare data, it's one we can actually go answer and use to confirm existing SSPs or build new ones specific to that population. 

More to come soon

Once the claims data starts flowing, it's a field day for us healthcare data enthusiasts. Look out for future reporting on the scintillating insights we find.

Drug manufacturer's guide to Transparency in Coverage's prescription drug file
Prescription Drug Machine-Readable File
3/21/25

Drug manufacturer's guide to Transparency in Coverage's prescription drug file

It's about time drugs prices got a dust-off

Life Sciences
Can price transparency replace UDS data for brokers?
Negotiated rates insights
2/27/25

Can price transparency replace UDS data for brokers?

Let’s take a look at the new kid on the block

Employers
Price transparency is one of the few bipartisan issues left
Price transparency regulations
2/25/25

Price transparency is one of the few bipartisan issues left

New executive order accelerates price transparency. Price transparency company goes bananas.

All
Price transparency regulations for pharma (2025)
Drug pricing policy
1/23/25

Price transparency regulations for pharma (2025)

Life Sciences--here’s your curtain call

Life Sciences
Drug price transparency data FAQ
Drug pricing data
1/22/25

Drug price transparency data FAQ

You know how it goes, “ask and…”

Payers
Drug pricing & reimbursement infusion confusion in 2025
Drug pricing data
1/13/25

Drug pricing & reimbursement infusion confusion in 2025

In this blog, we’re focused on understanding provider sensitivity to drug contracting mechanisms and how markups influence reimbursement.

Life Sciences
Reimbursement structure trends & what they mean for providers
Negotiated rates insights
1/7/25

Reimbursement structure trends & what they mean for providers

Let’s add “business intelligence" into the Price Transparency Cinematic Universe

Providers
Studies show price transparency is demystifying the healthcare market
Healthcare cost trends
1/7/25

Studies show price transparency is demystifying the healthcare market

From trauma centers to costs at large, we’re seeing things we’ve never seen before. Literally.

All
Can price transparency data replace claims data?
Negotiated rates insights
1/3/25

Can price transparency data replace claims data?

Survey says….

Payers

No results found

There are no results with this criteria. Try changing your search.